Gastric Cancer最新文献

{"title":"Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning.","authors":"Adila Abdulla, Chao Li","doi":"10.1007/s10120-025-01713-8","DOIUrl":"10.1007/s10120-025-01713-8","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"478-479"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metagenomic analysis of the intragastric and oral microbiome associated with gastric carcinogenesis after Helicobacter pylori eradication.","authors":"Masanori Matsumoto, Akiko Shiotani, Motoyasu Osawa, Osamu Handa, Hiroshi Matsumoto, Eiji Umegaki, Hideo Yonezawa, Takako Osaki","doi":"10.1007/s10120-026-01720-3","DOIUrl":"10.1007/s10120-026-01720-3","url":null,"abstract":"<p><p>BACKGROUND: Few reports have investigated bacterial microbiome in relation to gastric cancer after eradication of Helicobacter pylori (H. pylori). We aimed to conduct a genetic analysis of the gastric and oral microbiome, to identify its association with development of gastric cancer after H. pylori eradication. METHODS: The patients with prior endoscopic submucosal dissection (ESD) history after eradication (cancer patients) and control patients after eradication who underwent upper gastrointestinal endoscopy at Kawasaki Medical School Hospital from May 2021 to March 2023 were enrolled. Saliva and gastric mucus samples were collected and profiled by 16S rRNA gene amplicon sequencing. RESULTS: The subjects consisted of 24 cancer patients and 27 controls. The abundance of the genus Rothia in gastric mucus of the cancer patients was significantly higher compared to the controls. Conversely, the genus Parvimonas was significantly less abundant in the cancer patients. These differences in salivary samples between the two groups were not observed. The abundance of the genus Parvimonas in the gastric mucous was associated with the gastric atrophy, but genus Rothia was not. CONCLUSIONS: Genus Rothia may have some influence on carcinogenesis following H. pylori eradication.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"338-346"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese gastric cancer treatment guidelines 2025 (7th edition).","authors":"","doi":"10.1007/s10120-025-01698-4","DOIUrl":"10.1007/s10120-025-01698-4","url":null,"abstract":"<p><p>The 7th edition of the Gastric Cancer Treatment Guidelines was published in March 2025 covering new evidences. Following the format of the previous edition, this guideline consists of a text-based “Treatment” section and a “Clinical Questions” section that includes recommendations and explanations for clinical questions. The Treatment section describes the established standard treatments for gastric cancer, including surgery, endoscopic resection, and chemotherapy. The Clinical Questions section is based on a literature search and evaluation by the independent systematic review team. This allows for evidence-based responses to clinical issues and also presents future research topics in gastric cancer treatment.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"271-299"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12956939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Textbook outcome in gastric cancer surgery: a multicenter cohort study and proposal for a new specific index (TOGS).","authors":"Daniele Marrelli, Ludovico Carbone, Stefania Angela Piccioni, Lorena Torroni, Elio Treppiedi, Silvia Ministrini, Leonardo Solaini, Rossella Reddavid, Marina Valente, Laura Fortuna, Stefano De Pascale, Mattia Berselli, Cecilia Ridolfi, Luigina Graziosi, Flavia Carlini, Pietro Maria Lombardi, Stefano Rausei, Fausto Rosa, Giovanni Camerini, Annibale Donini, Gianluca Garulli, Eugenio Cocozza, Uberto Fumagalli Romario, Fabio Cianchi, Federica Filippini, Paolo Morgagni, Ugo Elmore, Federico Marchesi, Maurizio Degiuli, Giorgio Ercolani, Guido Alberto Massimo Tiberio, Simone Giacopuzzi, Riccardo Rosati, Franco Roviello","doi":"10.1007/s10120-025-01710-x","DOIUrl":"10.1007/s10120-025-01710-x","url":null,"abstract":"<p><p>BACKGROUND: Textbook Outcome (TO) combines optimal surgical outcomes into a single measure. This study evaluates achievement of TO using a multicenter database, assessing hospital variation, its correlation with early and late results, and refining a tailored definition of Textbook Outcome in Gastric Surgery (TOGS). METHODS: Data from patients undergoing curative gastrectomy (2011–2020) in Italian centers affiliated to the Italian Gastric Cancer Research Group (GIRCG) were analyzed. TOGS was introduced at the 2024 GIRCG Annual Meeting in Siena (Italy). RESULTS: Among 1988 patients (median age 72 years, BMI 24.9 kg/m2), 1523 underwent surgery in higher-volume centers (≥ 30 cases per year) and 465 in lower-volume centers (15–30 cases per year). TO was achieved in 54.6% of patients (55.2% in higher-volume vs. 52.7% in lower-volume centers, P = 0.350). Clavien-Dindo grade II or higher complications (34.8%) and re-interventions (11.5%) mostly affected the achievement of TO. Younger age (P < 0.001), early stages (P < 0.001), female gender (P = 0.005), open approach (P = 0.008) and absence of extensive surgery (P = 0.033) were independent predictors of TO. Patients achieving TO showed better survival (5-y 69.8% vs. 57.3%, HR 0.63 [95% CI, 0.54–0.75], P < 0.001), also when stratifying for tumor stages. The new TOGS definition, based on specific criteria for gastric surgery, reduced its achievement rate (50.2%) but shortened mean hospital stay (8.9 vs. 18 days) and increased the likelihood of long-term survival. CONCLUSIONS: TO and TOGS are valuable metrics for assessing hospital performance and optimizing outcomes following gastrectomy for gastric cancer. Hospital volume did not impact TO and TOGS rates in GIRCG centers.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"452-464"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations of Helicobacter pylori-attributable gastric cancer estimates in Albania.","authors":"Bledar Kraja, Genc Burazeri","doi":"10.1007/s10120-025-01712-9","DOIUrl":"10.1007/s10120-025-01712-9","url":null,"abstract":"","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"476-477"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital variation in surgical outcomes for gastric cancer: the impact of case-mix and treatment across a global cohort.","authors":"Sander J M van Hootegem, Margrietha van der Linde, Marcel A Schneider, Jeesun Kim, Felix Berlth, Yutaka Sugita, Peter P Grimminger, Gian Luca Baiocchi, Giovanni De Manzoni, Maria Bencivenga, Suzanne S Gisbertz, Souya Nunobe, Han-Kwang Yang, Christian A Gutschow, Sjoerd M Lagarde, Hester F Lingsma, Bas P L Wijnhoven","doi":"10.1007/s10120-025-01696-6","DOIUrl":"10.1007/s10120-025-01696-6","url":null,"abstract":"<p><strong>Background: </strong>There is substantial global variation in demographics, disease burden, and treatment for gastric cancer patients. Benchmarking is an instrument to assess such variation and enables to investigate to which extent case-mix and treatments explain differences in outcomes. We aimed to evaluate hospital-level variation in surgical outcomes following gastrectomy for gastric cancer before and after adjusting for case-mix and treatment-related factors.</p><p><strong>Methods: </strong>Data were retrieved from the GastroBenchmark and GASTRODATA databases, including consecutive gastric cancer resections performed between 2017 and 2021 from 43 centers. Patients who underwent a (sub)total gastrectomy for adenocarcinoma were identified. Outcomes included 30-day mortality, severe complications (Clavien-Dindo grade ≥ 3a), > 15 lymph nodes retrieved, negative resection margin (R0), prolonged hospitalization (> 14 days), readmissions (< 30 days), reoperations, and escalation of care. We assessed absolute inter-hospital variation for outcomes, and estimated outcomes using mixed-effect logistic regression models with a random intercept. We estimated crude, case-mix adjusted, and case-mix and treatment adjusted hospital effects. The conditional and marginal pseudo-R² were used to quantify the variance in outcome explained by case-mix and treatment-related factors.</p><p><strong>Results: </strong>A total of 7818 patients from 41 hospitals were included, with contributions ranging from 12 to 2554 patients per hospital (IQR: 49-146). Observed 30-day mortality and severe complications ranged from 0 to 9.7% (IQR: 3.2%) and 5.3 to 31% (IQR: 7.7%), respectively. Larger variation between hospitals was observed for retrieval of > 15 lymph nodes (IQR: 12.3%), prolonged hospitalization (IQR: 14.4%) and readmissions (IQR 11.3%). This variation was reduced in the crude model, while adjusting for case-mix and treatment-related factors did not significantly reduce variation for any outcome. Case-mix factors had a limited contribution to the explained variance, except for 30-day mortality (33.9%) and negative resection margins (31.7%). Adding treatment-related factors increased the explained variance for 30-day mortality by 40.8%, but had low impact (< 10%) on the variance in most surgical outcomes.</p><p><strong>Conclusions: </strong>Case-mix and treatment factors are not the primary drivers of variation in surgical outcomes following gastrectomy. Case-mix adjustment can improve the validity of global comparisons for 30-day mortality, but does not seem essential for comparing other investigated outcomes.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"424-432"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibody-drug conjugates in gastric cancer: clinical advances and resistance mechanisms.","authors":"Wenke Li, Mo Cheng, Hongyan Han, Menghui Xu, Yiqiao Luo, Feng Bi, Ming Liu","doi":"10.1007/s10120-025-01703-w","DOIUrl":"10.1007/s10120-025-01703-w","url":null,"abstract":"<p><p>Gastric cancer remains a major clinical challenge owing to its insidious onset and marked heterogeneity, which contribute to poor prognosis and limit the effectiveness of chemotherapy‑based systemic therapy. Antibody‑drug conjugates (ADCs) deliver potent cytotoxins to tumor cells with antigen specificity and have emerged as a therapeutic class that can enhance efficacy while reducing off‑target toxicity. Recent trials of ADCs targeting HER2, CLDN18.2, TROP2, CEACAM5/6, and HER3 demonstrate substantial therapeutic activity. Notably, the HER2‑directed agents trastuzumab deruxtecan and disitamab vedotin have improved survival and response in previously treated advanced disease. ADCs targeting CLDN18.2 and TROP2 have also yielded encouraging early results. Accumulating evidence from ongoing programs indicates movement into earlier lines of therapy in advanced gastric cancer, including evaluation in first‑line combination regimens. Broader clinical use has highlighted resistance mechanisms, including antigen loss or heterogeneity, impaired internalization and lysosomal processing, increased drug efflux, and an immunosuppressive tumor microenvironment that limits delivery. This review synthesizes clinical advances in ADC therapy for gastric cancer, delineates resistance biology, and evaluates strategies to overcome therapeutic resistance. Deeper mechanistic insight, biomarker‑guided patient selection, and continued innovation in targets, linkers, payloads, and rational combinations will be critical to overcome resistance and improve outcomes for patients with gastric cancer.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"300-320"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902).","authors":"Shunji Endo, Ryo Tanaka, Toshifumi Yamaguchi, Hiromichi Miyagaki, Junji Kawada, Takeshi Omori, Naoki Takahashi, Toru Masuzawa, Haruna Furukawa, Yuya Sato, Atsushi Takeno, Naoki Shinno, Ryohei Kawabata, Shinsuke Katsuyama, Shigeyoshi Higashi, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh","doi":"10.1007/s10120-025-01705-8","DOIUrl":"10.1007/s10120-025-01705-8","url":null,"abstract":"<p><strong>Background: </strong>Large type 3 (≥ 8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors.</p><p><strong>Methods: </strong>Eligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40 mg/m², oxaliplatin 100 mg/m², and oral S-1 at 80 mg/m²/day for 14 days), followed by gastrectomy with ≥ D2 lymphadenectomy and one year of adjuvant docetaxel plus S-1. The primary endpoint was the 3 year progression-free survival (PFS) rate, with an expected value of 60% and a threshold of 45%. A one-sample log-rank test was performed with an α level of 0.10.</p><p><strong>Results: </strong>Of the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1-50.6%; 80% CI 28.6-46.4%; p = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2-65.0%).</p><p><strong>Conclusions: </strong>Although neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"387-397"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146010101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative albumin grip index as a novel biomarker predicting prognosis and postoperative complications after gastrectomy for gastric cancer.","authors":"Katsunobu Sakurai, Naoshi Kubo, Tatsuro Tamura, Yutaka Tamamori, Tsuyoshi Hasegawa, Junya Nishimura, Yasuhito Iseki, Tatsunari Fukuoka, Takafumi Nishii, Masakazu Yashiro, Kiyoshi Maeda","doi":"10.1007/s10120-026-01715-0","DOIUrl":"10.1007/s10120-026-01715-0","url":null,"abstract":"<p><p>BACKGROUND: The increasing number of elderly patients with gastric cancer (GC) highlights the need for accurate prognostic assessment. Although several nutrition-related biomarkers have been proposed, their predictive abilities remain limited. Precise prediction of surgical outcomes is particularly important in elderly patients with reduced nutritional and physical reserves. METHODS: We developed a novel biomarker, the Albumin Grip Index (AGI), which was calculated as 10 × serum albumin (g/dL) + grip strength [kilogram-force (kgf)] to evaluate both nutritional and physical status. We retrospectively investigated 370 patients who underwent gastrectomy for GC from January 2016 to December 2023. Patients were divided into high and low AGI groups to examine its impact on overall survival (OS), cancer-specific survival (CSS), and major complications ( ≧ Clavien-Dindo grade 3). The prognostic performance of AGI was compared with other albumin-based biomarkers: Geriatric Nutrition Risk Index (GNRI), Prognostic Nutritional Index (PNI), and modified Glasgow Prognostic Score (mGPS). RESULTS: Low AGI was significantly associated with older age, malnutrition, impaired physical function, and advanced disease. The 5-year OS and CSS rates were significantly lower in the low AGI group than in the high AGI group. Major complications were also more frequent in the low AGI group. Multivariate analysis identified low AGI as an independent predictor of OS, CSS, and major complications. AGI showed superior prognostic performance to other albumin-based indices. CONCLUSIONS: AGI is a simple and clinically practical biomarker integrating nutritional and physical status, and it effectively predicts survival and postoperative complications after gastrectomy for GC.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"465-475"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frizzled-1 amplification promotes fibrosis in the gastric tumor microenvironment through the activation of fibroblasts via the SLIT2/ROBO1 axis.","authors":"Yilin Tong, Takashi Semba, Akiho Nishimura, Atsuko Yonemura, Masaya Yamazaki, Huaitao Wang, Lingfeng Fu, Yuya Okamoto, Takahiro Shoda, Takuya Tajiri, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Masaaki Iwatsuki, Takatsugu Ishimoto","doi":"10.1007/s10120-025-01701-y","DOIUrl":"10.1007/s10120-025-01701-y","url":null,"abstract":"<p><strong>Background: </strong>A fibrotic tumor microenvironment (TME) promotes tumor progression by the interactions between tumor cells and cancer-associated fibroblasts (CAFs) in the extracellular matrix (ECM), which enhance tumor cell survival and growth, and by suppressing antitumor immunity. However, how characteristic gene expression and amplification in cancer cells drive the formation of a fibrotic TME in patients with gastric cancer (GC) is unclear.</p><p><strong>Methods: </strong>We performed genomic and transcriptomic analyses via datasets from The Cancer Genome Atlas and the Asian Cancer Research Group to identify amplified and overexpressed genes associated with the presence of a fibrotic TME in tumors. Syngeneic mouse models of GC and multiplexed immunohistochemistry (IHC) were used to validate the findings of the transcriptomic analysis and investigate the underlying mechanisms.</p><p><strong>Results: </strong>The Frizzled class receptor 1 (FZD1) gene was frequently amplified and highly expressed in GC patients with fibrotic tumors, and FZD1 expression was related to a poor prognosis. The overexpression of Fzd1 in murine GC tumor cells was significantly associated with enhanced tumor fibrosis and growth and reduced infiltration of CD3⁺ lymphocytes and CD8⁺ T cells into tumors. SLIT2 secretion was increased in Fzd1-overexpressing tumor cells via the canonical WNT-β-catenin pathway, and SLIT2 activated CAFs to produce more ECM through the SLIT2‒ROBO1 axis.</p><p><strong>Conclusions: </strong>This study highlights the potential of FZD1 as a biomarker for predicting fibrotic status in patients with GC and the SLIT2‒ROBO1 axis as a therapeutic target to reverse a fibrotic and immunosuppressive TME.</p>","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"323-337"},"PeriodicalIF":6.1,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}